Sarepta's Former COO David Howton Sold $31.2M — Now Selling SLDB Stock at $6/Share
David Howton, former COO of Sarepta Therapeutics, sold $31.2M in SRPT stock. Now at Solid Biosciences, his recent filings show SLDB sales at just $5.82-$6.44/share.
David T. Howton, former COO of Sarepta Therapeutics (SRPT), accumulated $31.2 million in career stock sales across 120 transactions. Now at Solid Biosciences (SLDB), his February 2026 filings show a starkly different scale: selling 45,240 shares of SLDB at just $5.82-$6.44/share for roughly $286K total.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $31.2M |
| Career Buy Value | $0 |
| Total Transactions | 120 |
| Last Transaction | 2026-02-02 |
| Shares Remaining | 105,077 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-02-18 | Sell | 7,469 | $5.8233 | $43K |
| 2026-02-13 | Exercise | 14,687 | N/A | $0 |
| 2026-02-13 | Exercise | 14,687 | N/A | $0 |
| 2026-02-02 | Sell | 37,771 | $6.4369 | $243K |
| 2026-01-31 | Exercise | 42,275 | N/A | $0 |
Howton's transition from Sarepta to Solid Biosciences is visible in his Form 4 timeline. January-February 2026 filings show systematic SLDB option exercises (42K-79K shares) followed by sales at single-digit prices. The contrast with his Sarepta tenure — where individual transactions could reach millions — highlights the difference between a $10B+ rare disease leader and a $250M gene therapy company.
What It Means
Howton's career insider profile tells a story of two acts: $31.2M in Sarepta sales at premium biotech prices, followed by small-dollar SLDB selling at depressed valuations. The 105,077 shares remaining across his filings suggest he maintains meaningful exposure, but at ~$6/share that represents only ~$630K — a fraction of what a single Sarepta sale generated.
The Sarepta-to-Solid-Biosciences career path is common in biotech: executives move from established rare disease companies to earlier-stage gene therapy plays. For SRPT investors, Howton's departure and complete divestiture removes a long-tenured operator from the shareholder base. For SLDB watchers, a former Sarepta COO selling at $6 from a company developing DMD gene therapies adds an insider sentiment data point — though early-stage biotech selling is often driven by exercise deadlines rather than conviction.
What to Watch
- Whether Howton continues exercising and selling SLDB options in Q1 2026
- Solid Biosciences' DMD gene therapy clinical data readouts
- Sarepta's Elevidys commercial trajectory under new leadership
- Any additional career moves that generate new Form 4 filings
Related Research
Explore all researchVictory Capital kept mega-cap tech on top in Q4 2025, but the sharper signal was in the secondary moves: large increases in Netflix, Constellation Energy, TSMC and new positions like IQVIA. The next filing will show whether that diversification continues.
Apr 17, 2026
Fisher’s Q4 2025 filing was still packed with mega-cap tech, but the bigger tell was a giant Treasury and investment-grade corporate bond sleeve built through IEF and VCIT. The next filing will show whether that duration bet was tactical or structural.
Apr 17, 2026
FIL Ltd's Q4 2025 13F shows $133.60B in reported value, led by MSFT and a diversified institutional tail.
Apr 24, 2026
Janus Henderson kept Nvidia and Microsoft on top in Q4 2025, but the more interesting signal was underneath: new exposure to Intuitive Surgical, Protagonist Therapeutics and other growth-healthcare names. The next filing will show whether that rotation keeps building.
Apr 17, 2026
Raymond James used Q4 2025 to keep broad ETF exposure high through VOO, AGG, SPY and IEFA while also adding to sector sleeves such as XLK and XLE. The next filing will show whether that balanced ETF-heavy structure remains the preferred setup.
Apr 17, 2026